The question of what is the safest injection for osteoporosis has no single answer. No injectable therapy is free of adverse effects, and osteoporosis injection risks differ considerably from one drug class to the next.
This side effect comparison from Medica Depot covers the osteoporosis injection category so clinicians can weigh agent-specific side effects rather than generalities. A practice deciding whether to buy osteoporosis injection stock for its patients should weigh safety and tolerability alongside fracture-prevention data.
In this article, learn the documented side effects of bisphosphonate injections, teriparatide (Forteo®), abaloparatide (Tymlos®), and romosozumab (Evenity®), including how severe and long-lasting each is and how clinicians avoid or manage them.
Key Takeaways
- Each injectable class has a different risk signature: infusion reactions and rare jaw or femur events (bisphosphonates), transient heart-rate rises, dizziness, and nausea (Forteo® and Tymlos®), and cardiovascular warnings (Evenity®).
- No head-to-head trial ranks these drugs by safety, so “safest” depends on the patient’s kidney function, calcium status, and cardiovascular history.
- Most serious risks can be reduced with pre-treatment screening and simple monitoring.
About: Medica Depot is your trusted all-in-one supplier, offering a range of high-quality medical injectables and supplies. We offer a worry-free experience in searching for the best and most popular products on the market, like osteoporosis injections. Whether for health professionals, plastic surgeons, dermatologists, licensed estheticians, or other specialists, we can offer genuine, brand-name products you may need. With Medica Depot, we prioritize serving you better to improve the patient’s quality of life.
Which Injectable Medications Are Used to Treat Osteoporosis?
Four options anchor the safety comparison for osteoporosis medications.
- Zoledronic acid (Reclast®) is a bisphosphonate given by intravenous infusion and is approved for postmenopausal osteoporosis.[1]
- Teriparatide (Forteo®) is a synthetic version of parathyroid hormone.
- Abaloparatide (Tymlos®) is a synthetic analog of parathyroid hormone-related peptide. Both are given as a daily subcutaneous injection.[2][3]
- Romosozumab (Evenity®) is a monoclonal antibody given monthly under the skin for 12 months.[4][5]
What Side Effects Can Come From Osteoporosis Injections?
Nausea, headache, and dizziness are common complaints with daily hormone-analog injections.[2][3] Serious adverse effects are less frequent and differ by drug. They include osteonecrosis of the jaw and atypical femur fractures with bisphosphonates,[1] and calcium disturbances with bisphosphonates and Evenity®.[1][4] Evenity® also carries a risk of heart attack and stroke.[4]
In the large ARCH trial of 4,093 postmenopausal women, overall and serious adverse events were balanced between romosozumab and alendronate.[5]
What Should Clinicians Know About Bisphosphonate Injection Risks?
- Acute phase reaction: After zoledronic acid infusion, flu-like illness, fever, muscle pain, joint pain, and bone pain occurred in 25% of patients, versus 8% in a risedronate comparison group. These symptoms cluster in the first days after the infusion.[1]
- Calcium levels in the blood: Zoledronic acid is contraindicated in patients with hypocalcemia, and low calcium may worsen during treatment. Clinicians should correct it first with calcium and vitamin D.[1]
- Kidney effects: The label contraindicates zoledronic acid when creatinine clearance is below 35 mL/min. Risk of acute renal impairment is higher in older patients, those on diuretics, and those who are dehydrated.[1]
- Long-term use of bisphosphonates: Osteonecrosis of the jaw and atypical femur fractures are rare but recognized. Patients are told to report new thigh, hip, or groin pain, which can precede an atypical fracture.[1] In ARCH, adjudicated events during the alendronate phase were few: one case of jaw osteonecrosis in each group, and two atypical femoral fractures versus four.[5] Allergic reactions, including anaphylaxis, have also been reported.[1]
Comparing the Side Effects of Forteo® and Tymlos®
Both drugs are given daily, and both are generally well tolerated. In the pivotal teriparatide fracture trial of 1,637 postmenopausal women, side effects were generally mild, with nausea, headache, dizziness, and leg cramps reported.[2] The ACTIVE trial then compared abaloparatide, teriparatide, and placebo directly for 18 months in 2,463 women, and overall adverse events did not differ between groups.[3]
Which Reactions Are Linked to Teriparatide (Forteo®)?
In ACTIVE, nausea affected 5.1% of teriparatide patients versus 3.0% on placebo, and palpitations 1.6% versus 0.4%. Dizziness was similar to placebo (7.3% versus 6.1%).[3] Heart rate rose by about 5 beats per minute one hour after dosing, compared with about 1 beat per minute on placebo. Serious cardiac events were similar across groups (1.0% versus 0.9%).[3]
Which Reactions Are Linked to Abaloparatide (Tymlos®)?
In the ACTIVE trial, abaloparatide produced more of these reactions than teriparatide. Palpitations occurred in 5.1% of patients (0.4% on placebo), dizziness in 10.0% (6.1%), nausea in 8.3% (3.0%), and tachycardia in 1.3% (0.4%).[3] Heart rate rose by about 8 beats per minute one hour after the first dose; in a healthy-volunteer study, this increase resolved within about four hours. Blood pressure fell only 1–3 mmHg more than on placebo.[3]
Discontinuation for these events was uncommon but higher with abaloparatide: 3.3%, versus 1.3% with teriparatide and 0.6% with placebo. Serious cardiac events did not increase.[3] The trial excluded women with symptomatic hypotension, marked orthostatic blood pressure drops, or significant cardiovascular disease, so the reassurance may not extend to those patients.[3]
Evenity®’s Boxed Warning – What Are the Possible Risks?
Evenity® carries a boxed warning stating it may increase the risk of heart attack, stroke, and cardiovascular death. It should not be started in anyone who had a heart attack or stroke within the preceding year, and it should be stopped if either occurs.[4]
The trial data explain why. In the alendronate-controlled study (ARCH trial), heart attack occurred in 16 women (0.8%) on Evenity® versus 5 (0.2%) on alendronate.[4] Serious cardiovascular events were 2.5% versus 1.9% in year one.[5] The placebo-controlled study (FRAME trial) showed no imbalance: heart attacks occurred in 0.3% versus 0.2%, and strokes in 0.2% versus 0.3%.[4] Hypocalcemia can also occur and should be corrected before starting.[4]
Treatment is a fixed course of 12 monthly doses,[5] so the cardiovascular exposure window is defined.
What Is the Safest Injection for Osteoporosis? Weighing the Risk Profiles
No trial compares all four for safety, so the answer is patient-specific. Cardiovascular history argues against Evenity®,[4] while creatinine clearance below 35 mL/min rules out zoledronic acid.[1]
Patients with cardiovascular disease or symptomatic low blood pressure fall outside the ACTIVE evidence base for abaloparatide and teriparatide, so they warrant closer clinical judgment.[3]
For patients with osteoporosis and low bone mass at high fracture risk, untreated fracture risk is itself a safety issue. Evenity® produced a lower fracture risk than alendronate in ARCH.[5] This risk-first framing sits alongside broader osteoporosis treatment guidelines that shape when and how each agent enters a patient’s regimen.
The table below summarizes the main safety differences across the four injectable options.
| Option | Notable risks | Typical timing |
| Zoledronic acid | Acute phase reaction; kidney, calcium, rare jaw and femur events | Reaction in first days; rare events with long exposure [1] |
| Forteo® | Nausea, headache, dizziness, transient heart-rate rise | Within about an hour of dosing [2][3] |
| Tymlos® | Palpitations, dizziness, nausea, transient heart-rate rise | Resolves within about 4 hours in healthy volunteers [3] |
| Evenity® | Boxed warning for heart attack, stroke, cardiovascular death | During the 12-month course [4][5] |
What Steps Can Help Reduce or Prevent Injection Side Effects?
Most measures happen before the first dose.
- Screen calcium, vitamin D, and kidney function. This applies to bisphosphonates, and calcium correction also applies to Evenity®.[1][4]
- Assess cardiovascular history before Evenity®. Monitor for heart attack and stroke symptoms throughout.[4]
- Counsel on transient effects. Tell patients that dizziness, nausea, and palpitations can follow Forteo® or Tymlos® injections and that the heart-rate rise is short-lived.[3]
- Track treatment duration. The head-to-head safety data for both drugs cover 18 months of daily treatment.[3]
- Counsel on thigh or groin pain and jaw symptoms with bisphosphonates.[1]
Persistent or worsening back pain deserves a clinical work-up rather than an assumption that it is a drug effect. New vertebral fractures are a primary or key secondary endpoint in most osteoporosis trials and a common cause of chronic back pain in this population.[5]
The contents of this page are meant for licensed medical professionals. They serve informational purposes only and are not to be taken as medical advice.
Citations
[1] National Library of Medicine. “RECLAST® (Zoledronic Acid) Injection, Solution: Prescribing Information.” DailyMed, updated 3 Feb. 2026, dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=5a9b3737-9ce6-4a89-b76e-6aab79eba9cf.
[2] Neer, R M et al. “Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis.” The New England journal of medicine vol. 344,19 (2001): 1434-41. doi:10.1056/NEJM200105103441904
[3] Cosman, Felicia et al. “Cardiovascular Safety of Abaloparatide in Postmenopausal Women With Osteoporosis: Analysis From the ACTIVE Phase 3 Trial.” The Journal of clinical endocrinology and metabolism vol. 105,11 (2020): 3384–3395. doi:10.1210/clinem/dgaa450
[4] Amgen Inc. “EVENITY® (Romosozumab-aqqg) Injection, for Subcutaneous Use: Full Prescribing Information.” Amgen, revised Jan. 2026, www.pi.amgen.com/-/media/Project/Amgen/Repository/pi-amgen-com/Evenity/evenity_pi_hcp_english.pdf.
[5] Saag, Kenneth G et al. “Romosozumab or Alendronate for Fracture Prevention in Women with Osteoporosis.” The New England journal of medicine vol. 377,15 (2017): 1417-1427. doi:10.1056/NEJMoa1708322
This content was prepared and reviewed under our editorial guidelines , which govern how we source, verify, and update clinical and product information. Every claim is checked against peer-reviewed research, manufacturer documentation, or regulatory guidance before publication.
